Nature of the Event

Sai Life Sciences Limited has made a regulatory disclosure to the National Stock Exchange of India Limited (NSE) and BSE Limited regarding the allotment of equity shares under its Employees Stock Option Plan 2008 (ESOP 2008). The disclosure is made pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Key Quantitative Figures

  • Number of equity shares allotted: 24,000
  • Face value of each share: ₹1
  • Pre-allotment issued, subscribed, and paid-up equity share capital: ₹21,23,94,217
  • Post-allotment issued, subscribed, and paid-up equity share capital: ₹21,24,18,216
  • Exercise price per share: ₹188.90
  • Premium per share: ₹187.90
  • ISIN of the shares: INE570L01029
  • Total issued shares after this allotment: 21,24,18,216

Dates of Action

  • Date of Board approval via Circular Resolution: 18th September 2026
  • Date of issue of shares: 18-09-2026
  • Previous filing date of the statement referred to in regulation 10(b) of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021: 08th January 2025

Parties or Entities Involved

  • Stock Exchanges: BSE Limited (BSE Scrip code: 544306) and National Stock Exchange of India Limited (NSE Symbol: SAILIFE)

Capital Structure Impact

The allotment of 24,000 equity shares resulted in an increase of the company's paid-up equity share capital. The distinctive numbers of the shares allotted range from 21,23,94,217 to 21,24,18,216 (both inclusive). The new shares are identical in all respects to the existing equity shares of the company. There is no lock-in period applicable to these shares.

Additional Details from Annexure

The annexed details, required under Regulation 10(c) of SEBI ESOP Regulations 2021, confirm the title of the scheme as 'Employees Stock Option Plan 2008'. The security issued is equity shares, and no share certificate numbers are applicable as the shares were issued in dematerialized form. No listing fees are payable for this issuance.

#Tags: #SaiLifeSciences #ESOP #SEBIDisclosure #RegulatoryCompliance #CapitalIncrease